NSE · WOCKPHARMA
Wockhardt Limited
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹580 Cr with net profit ₹100 Cr — a 17.24% net margin, versus 19.07% the period before.
Shareholding
As of 2026-09-30
- Promoter49.33%
- Public35.8%
- FII7.02%
- DII7.85%
1,73,116 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 2.23× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Pharmaceuticals - Indian - Bulk Drugs & Formln · ranked #18 of 102 by market cap · medians across 49 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | ₹4,46,276 Cr | 36.26 | 5 | 13.79% | 17.89% |
| Laurus Labs Limited | ₹1,26,433 Cr | 94.35 | 20.82 | 22.11% | 17.13% |
| Zydus Lifesciences Ltd. | ₹1,19,491 Cr | 26.29 | 4.29 | 15.1% | 14.11% |
| Dr Reddys Laboratories Ltd. | ₹1,14,683 Cr | 40.96 | 2.95 | 7.21% | 8.49% |
| Cipla Ltd. | ₹1,13,991 Cr | 36.71 | 3.22 | 8.18% | 10.39% |
| Mankind Pharma Limited | ₹1,04,913 Cr | 44.96 | 5.97 | 12.76% | 14.58% |
| Aurobindo Pharma Ltd. | ₹1,03,568 Cr | 25.52 | 2.62 | 10.13% | 10.88% |
| Lupin Limited | ₹90,914 Cr | 16.14 | 3.78 | 21.65% | 17.07% |
| Glenmark Pharmaceuticals Ltd. | ₹73,096 Cr | 23.42 | 6.53 | 18.07% | 9.22% |
| Alkem Laboratories Ltd. | ₹63,334 Cr | 27.79 | 4.56 | 16.66% | 14.31% |
| Wockhardt Limited(this company) | ₹31,641 Cr | 79.11 | 6.13 | 7.95% | 10.93% |
AI analysis
AI-generated · google/gemini-2.5-flashWockhardt Limited is listed with a market capitalization of Rs 31254 Cr. The company reported a revenue of Rs 3074 Cr with a revenue growth of 7.7% and a profit margin of 6.31%. Earnings per share (EPS) stood at Rs 17.48. The stock's 52-week high is Rs 2422.3 and its 52-week low is Rs 1086.7.
Positives
- +Revenue grew 7.7% to Rs 3074 Cr for the period ended March 2025.
- +Debt-to-equity ratio is 0.57, indicating moderate leverage.
Negatives
- −Promoter holding has decreased from 74.16% in December 2016 to 49.08% in March 2026.
- −18.82% of promoter shares are pledged as of March 31, 2026.
- −The profit margin is relatively low at 6.31%.
- −The company reported a negative net profit of -Rs 47 Cr for the period ended March 2025.
- −Wockhardt Limited is listed under LT-ASM (Additional Surveillance Measure) surveillance.
Financial Performance
For the period ended March 2026, Wockhardt Limited reported a revenue of Rs 516 Cr. This follows quarterly revenues of Rs 430 Cr in December 2025, Rs 380 Cr in September 2025, and Rs 413 Cr in June 2025. The company's annual revenue for March 2025 was Rs 3074 Cr, reflecting a 7.7% growth. Net profit for March 2026 was Rs 167 Cr, up from Rs 28 Cr in December 2025.
Profitability & Returns
The company's profit margin stood at 6.31%. Return on Equity (ROE) was 5.75%, and Return on Capital Employed (ROCE) was 7.39%. For the March 2026 quarter, the company recorded a net profit of Rs 166 Cr on a revenue of Rs 965 Cr. The Earnings Per Share (EPS) for the latest available annual period was Rs 17.48.
Balance Sheet
Wockhardt Limited has a book value of Rs 304.03. The debt-to-equity ratio is 0.57. There is no information available regarding dividends, as the dividend yield is 0. The company's EPS for the year ended March 2025 was -Rs 3.02, with a net profit of -Rs 47 Cr.
Ownership & Pledges
As of March 31, 2026, promoter holding in Wockhardt Limited was 49.08%, with 18.82% of promoter shares pledged. Public shareholding was 32.83%, while FIIs held 7.08% and DIIs held 10.97%. The total number of shareholders was 139,016.
Regulatory & Surveillance
Wockhardt Limited is currently under LT-ASM surveillance, specifically categorized as ASM 1. This includes measures identified as LT-ASM and LT-ASM. This indicates heightened monitoring by regulatory authorities.
Data as of — price: 2026-11-07 · financials: Sep 26 · shareholding: Sep 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.